Aripiprazole
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Aripiprazole: From Schizophrenia / Bipolar Disorder to Major Affective Disorder
One-Sentence Summary
Aripiprazole is an atypical antipsychotic (second-generation) widely established for schizophrenia and bipolar I disorder, acting through a unique partial agonism profile at dopamine and serotonin receptors. The TxGNN model predicts it may be effective for Major Affective Disorder (encompassing major depressive disorder and bipolar-spectrum conditions), with multiple completed Phase 3 RCTs and 20 publications — including several high-quality systematic reviews and network meta-analyses — currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Schizophrenia / Bipolar I Disorder (established globally; no India regulatory data on file) |
| Predicted New Indication | Major Affective Disorder |
| TxGNN Prediction Score | 99.62% |
| Evidence Level | L1 |
| India Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Aripiprazole is a third-generation atypical antipsychotic with a distinctive triple mechanism: D2/D3 partial agonism stabilises dopaminergic tone without the full receptor blockade seen with older antipsychotics; 5-HT1A partial agonism delivers anxiolytic and antidepressant-like effects by modulating serotonergic signalling; and 5-HT2A antagonism potentiates conventional antidepressant activity. This mechanistic triad positions it as a natural adjunct to antidepressant therapy rather than a pure antipsychotic.
Major affective disorder — spanning major depressive disorder (MDD) and bipolar-spectrum illness — is fundamentally characterised by dysregulation of both dopaminergic and serotonergic circuits in prefrontal-limbic networks. The partial agonism profile of Aripiprazole is particularly suited to this pathophysiology: in hypodopaminergic states (as seen in depression), it provides net receptor activation, while in hyperdopaminergic states (as in mania), it acts as a functional antagonist. This “dopamine system stabiliser” property aligns directly with the mood-state instability that defines major affective disorders.
Regulatory and clinical evidence further reinforces the prediction. The US FDA has already approved Aripiprazole as adjunctive therapy for MDD (under the brand name Abilify), and approvals for acute mania and bipolar I maintenance exist across multiple jurisdictions. Several completed Phase 3 RCTs (including NCT00876343, n = 586 and NCT00095823, n = 1,200) provide direct, high-quality evidence of efficacy specifically in MDD populations who responded inadequately to SSRIs or SNRIs — precisely the clinical scenario the TxGNN model is capturing.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00876343 | Phase 3 | Completed | 586 | Double-blind, placebo-controlled RCT evaluating Aripiprazole vs placebo as adjunctive therapy to SSRI/SNRI in MDD; direct, highest-grade efficacy and safety evidence for this indication |
| NCT00095823 | Phase 3 | Completed | 1,200 | Large 14-week placebo-controlled RCT assessing Aripiprazole adjunctive to ongoing antidepressant in MDD; broad safety database |
| NCT02046564 | Phase 3 | Completed | 412 | Evaluated ASC-01 (aripiprazole/sertraline fixed combination) vs sertraline monotherapy in MDD with incomplete SSRI response |
| NCT00277212 | Phase 4 | Completed | 1,169 | Double-blind study of Aripiprazole + Lamotrigine in long-term maintenance of Bipolar I Disorder following manic/mixed episode |
| NCT00882362 | Phase 3 | Completed | 155 | Long-term (≥ 52-week) safety and efficacy of adjunctive Aripiprazole with SSRI/SNRI in MDD |
| NCT02305823 | Phase 4 | Completed | 203 | Head-to-head comparison of Aripiprazole, Quetiapine, and Ziprasidone in first-episode non-affective psychosis; provides comparative effectiveness context |
| NCT00107939 | Phase 3 | Completed | 453 | Licarbazepine as add-on to atypical antipsychotics (including Aripiprazole) in acute mania of Bipolar I; confirms Aripiprazole as a standard-of-care comparator arm |
| NCT00683852 | Phase 3 | Completed | 225 | Double-blind placebo-controlled study evaluating reduced-dose Aripiprazole in MDD patients with inadequate response to antidepressants; dose-optimisation data |
| NCT03423680 | Phase 3 | Recruiting | 390 | 8-week placebo-controlled RCT assessing Aripiprazole adjunctive to mood stabiliser in Bipolar I/II disorder with major depressive episode; results pending |
| NCT01111565 | Phase 3 | Terminated | 137 | Randomised double-blind study of oral Aripiprazole/Escitalopram combination in MDD with inadequate SSRI response; terminated early, provides limited safety data |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 38669232 | 2024 | Meta-analysis of RCTs | PLoS ONE | Largest meta-analysis evaluating Aripiprazole augmentation vs bupropion switching in TRD/MDD; confirms efficacy and characterises safety profile |
| 34986373 | 2022 | Systematic Review + NMA | J Affect Disord | Network meta-analysis comparing augmentation agents for treatment-resistant depression; Aripiprazole ranked among most evidence-supported options |
| 38219278 | 2024 | Systematic Review + NMA | Neuropsychopharmacology Reports | Direct comparison of brexpiprazole vs Aripiprazole in Japanese MDD patients with inadequate antidepressant response; supports ethnic generalisability |
| 37746943 | 2023 | NMA | Medicine | Network meta-analysis ranking 4 atypical antipsychotics (including Aripiprazole) as adjunctive treatment in MDD; provides comparative ranking of efficacy and tolerability |
| 35510505 | 2023 | Systematic Review + Meta-analysis | Psychological Medicine | Comprehensive meta-analysis of antipsychotics as monotherapy and adjunctive therapy in MDD; largest evidence synthesis to date |
| 34167174 | 2021 | Systematic Review + Meta-analysis | Prim Care Companion CNS Disord | Focused on long-term (≥ 6 months) efficacy and tolerability of adjunctive Aripiprazole in MDD; remission rates and adverse event profile at sustained follow-up |
| 37149344 | 2023 | Review | Psychiatr Clin North Am | Reviews antidepressants and atypical antipsychotics for TRD; positions Aripiprazole as a first-line augmentation agent with existing FDA approval |
| 36855876 | 2023 | Review | Am J Psychiatry | Examines role of antipsychotics (including Aripiprazole) in the evolving TRD treatment landscape; discusses mechanism and clinical positioning |
| 37815563 | 2023 | Review | JAMA | Comprehensive JAMA review on diagnosis and treatment of bipolar disorder (40 million patients worldwide); Aripiprazole cited as a guideline-endorsed agent |
| 25963405 | 2016 | Review | Asia-Pacific Psychiatry | Reviews mechanistic basis for antipsychotics as antidepressants; explains why Aripiprazole is effective only at sub-antipsychotic doses in affective disorders |
India Market Information
No India regulatory authorisations are currently on file for Aripiprazole in this dataset. The drug is recorded as not marketed with zero registered products.
Note: Aripiprazole (brand name Abilify and generics) has regulatory approvals in the US, EU, Japan, and many other markets. The absence of India registration data in this dataset may reflect a data gap rather than true non-availability. Independent verification via the CDSCO (Central Drugs Standard Control Organisation) database is recommended before drawing conclusions about India market status.
Safety Considerations
Drug Interactions (316 interactions on record):
The DDI database flags a total of 316 drug interactions for Aripiprazole. Key interactions identified include:
- Major interaction: Bupropion — risk of seizure threshold lowering and pharmacodynamic potentiation; requires careful monitoring if combined (particularly relevant given Bupropion is itself used in TRD augmentation strategies)
- Moderate interactions (selected clinically relevant examples):
- Clarithromycin — CYP3A4 inhibition may increase Aripiprazole plasma levels; dose adjustment may be needed
- Aprepitant — CYP3A4 inhibition; monitor for increased Aripiprazole exposure
- Cisapride — additive QT-prolongation risk; use with caution
- Anticholinergic agents (Atropine, Hyoscyamine, Clidinium) — additive anticholinergic burden; monitor in elderly patients
- Antidiabetic agents (Metformin, Canagliflozin, Pioglitazone, Acarbose, Alogliptin, Albiglutide, Acetohexamide, Chlorpropamide) — Aripiprazole may cause metabolic changes affecting glucose regulation; blood glucose monitoring recommended
For complete warnings and contraindications, please refer to the approved package insert, as this information is not available in the current dataset.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Aripiprazole has already obtained FDA approval as an adjunctive treatment for MDD, supported by multiple completed Phase 3 RCTs (including trials with over 1,000 participants) and high-quality systematic reviews and network meta-analyses placing it among the most evidence-supported augmentation agents for treatment-resistant depression. The TxGNN L1 evidence designation and 99.62% prediction score are both well-justified by the empirical literature. The primary constraint for the India market is the absence of local regulatory registration and the lack of package insert data in this dataset.
To proceed, the following is needed:
- India regulatory pathway: Verify current CDSCO status and determine whether a new drug application (NDA) or abbreviated pathway applies; if unregistered, initiate formal filing
- Package insert review: Download and parse the approved India/TFDA prescribing information to extract official warnings, contraindications, and special population guidance (currently blocking for formal safety screening)
- MOA documentation: Retrieve structured mechanism-of-action data from DrugBank API (DB01238) to complete mechanistic gap analysis
- Local pharmacovigilance plan: Given 316 DDI interactions on record and the Major interaction with Bupropion (a common co-prescribed agent in TRD), a structured drug interaction management protocol should be defined prior to any clinical deployment
- Biomarker-stratified sub-analysis: Emerging Phase 3 trial data (e.g., NCT06054321, NCT07153406) exploring biomarker-guided selection of Aripiprazole augmentation may inform which patient subpopulations derive the greatest benefit — monitor for results through 2029
This report is generated for research purposes only and does not constitute medical advice. All drug repurposing candidates require clinical validation before therapeutic application. Data cutoff: 2026-04-05.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.